Perspective Therapeutics (CATX) Stock Forecast & Price Target

Compare

1,391 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CATX Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Perspective

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CATX Stock 12 Month Forecast

Average Price Target

$14.11

▲(291.94% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is $14.11 with a high forecast of $18.00 and a low forecast of $6.00. The average price target represents a 291.94% change from the last price of $3.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,4.781538461538462,5.883076923076923,6.984615384615385,8.086153846153847,9.187692307692307,10.28923076923077,11.390769230769232,12.492307692307692,13.593846153846155,14.695384615384615,15.796923076923077,16.89846153846154,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,4.4823076923076925,5.2846153846153845,6.086923076923076,6.889230769230769,7.691538461538462,8.493846153846153,9.296153846153846,10.098461538461539,10.90076923076923,11.703076923076923,12.505384615384616,13.307692307692307,{"y":14.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,3.8584615384615386,4.0369230769230775,4.2153846153846155,4.3938461538461535,4.572307692307692,4.750769230769231,4.929230769230769,5.107692307692307,5.286153846153846,5.464615384615385,5.643076923076923,5.821538461538461,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.8,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$14.11

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Dai

UBS

$18

Buy

400.00%

Upside

Reiterated

08/22/25

Perspective Therapeutics (CATX) Receives a Buy from UBS

Justin Walsh

JonesTrading

$18

Buy

400.00%

Upside

Reiterated

08/15/25

Promising Clinical Pipeline and Strategic Investments Justify Buy Rating for Perspective TherapeuticsWe see expanding interest in Pb-212-based radiopharmaceuticals as a favorable development for CATX and continue to believe that the company's investments in a vertically integrated manufacturing/clinical development platform will prove prudent and increase its likelihood of becoming an acquisition target. We reiterate our Buy rating and $18 price target.

Oliver McCammon

LifeSci Capital

$17

Buy

372.22%

Upside

Reiterated

08/13/25

Positive Outlook for Perspective Therapeutics: Buy Rating Driven by Promising Clinical Developments and Strategic ProgressThis morning, Perspecve Therapeucs (NYSE: CATX) reported Q2 2025 earnings and provided a corporate update. As a reminder, Perspecve is progressing three Pb-212-based clinical-stage radiopharmaceucal therapies (RPTs), including the VMT-α-NET RPT that is designed to target and deliver Pb212 to SSTR2-expressing gastroenteropancreac neuroendocrine tumors (GEP-NETs), the MC1R-targeted VMT01 RPT for metastac melanoma, and PSV359 for FAP-expressing tumors. While today's earnings release (HERE) was brief, our clear area of focus for Perspecve is on the update that the Company plans to provide at ESMO in 1/2a study invesgang their VMT -α-NET RPT (see our note on the ESMO tles HERE).

Leonid Timashev

RBC Capital

$16

Buy

344.44%

Upside

Reiterated

08/13/25

RBC Capital Keeps Their Buy Rating on Perspective Therapeutics (CATX)

Jeff Jones

Oppenheimer

$15→$14

Buy

288.89%

Upside

Reiterated

08/13/25

Perspective Therapeutics (CATX) Gets a Buy from OppenheimerOppenheimer analyst Jeff Jones lowered the price target on Perspective Therapeutics Inc (NYSE: CATX) to $14.00 (from $15.00) while maintaining a Outperform rating.

Louise Chen

Scotiabank

$15

Buy

316.67%

Upside

Reiterated

07/10/25

Perspective Therapeutics (CATX) Receives a Buy from Scotiabank

Nicole Germino

Truist Financial

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Perspective Therapeutics (NYSE MKT: CATX) and PTC Therapeutics (NASDAQ: PTCT)

David Nierengarten

Wedbush

$11

Buy

205.56%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (NASDAQ: SKYE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Perspective Therapeutics (NYSE MKT: CATX)

Yuan Zhi

B.Riley Financial

$9→$12

Buy

233.33%

Upside

Reiterated

06/23/25

Perspective Therapeutics price target raised to $12 from $9 at B. RileyPerspective Therapeutics price target raised to $12 from $9 at B. Riley

Alec Stranahan

Bank of America Securities

Hold

66.67%

Upside

Reiterated

06/02/25

Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX)

Robert Burns

H.C. Wainwright

$10

Buy

177.78%

Upside

Reiterated

05/19/25

Optimistic Buy Rating for Perspective Therapeutics Amid Financial Stability and Promising Clinical Developments

Lila Implantra

TR | OpenAI - 4o

―

Hold

―

Upgraded

04/21/25

AI Generated ArticleAI Generated Article

Kemp Dolliver

Brookline Capital Markets

$11

Buy

205.56%

Upside

Initiated

03/10/25

Perspective Therapeutics initiated with a Buy at BrooklinePerspective Therapeutics initiated with a Buy at Brookline

Christopher Liu

Lucid Capital

$15→$20

Buy

455.56%

Upside

Reiterated

01/27/25

Perspective Therapeutics Inc (CATX) PT Raised to $20 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Perspective Therapeutics Inc (NYSE: CATX) to $20.00 (from $15.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Dai

UBS

$18

Buy

400.00%

Upside

Reiterated

08/22/25

Perspective Therapeutics (CATX) Receives a Buy from UBS

Justin Walsh

JonesTrading

$18

Buy

400.00%

Upside

Reiterated

08/15/25

Oliver McCammon

LifeSci Capital

$17

Buy

372.22%

Upside

Reiterated

08/13/25

Leonid Timashev

RBC Capital

$16

Buy

344.44%

Upside

Reiterated

08/13/25

RBC Capital Keeps Their Buy Rating on Perspective Therapeutics (CATX)

Jeff Jones

Oppenheimer

$15→$14

Buy

288.89%

Upside

Reiterated

08/13/25

Louise Chen

Scotiabank

$15

Buy

316.67%

Upside

Reiterated

07/10/25

Perspective Therapeutics (CATX) Receives a Buy from Scotiabank

Nicole Germino

Truist Financial

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Perspective Therapeutics (NYSE MKT: CATX) and PTC Therapeutics (NASDAQ: PTCT)

David Nierengarten

Wedbush

$11

Buy

205.56%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (NASDAQ: SKYE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Perspective Therapeutics (NYSE MKT: CATX)

Yuan Zhi

B.Riley Financial

$9→$12

Buy

233.33%

Upside

Reiterated

06/23/25

Perspective Therapeutics price target raised to $12 from $9 at B. RileyPerspective Therapeutics price target raised to $12 from $9 at B. Riley

Alec Stranahan

Bank of America Securities

Hold

66.67%

Upside

Reiterated

06/02/25

Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX)

Robert Burns

H.C. Wainwright

$10

Buy

177.78%

Upside

Reiterated

05/19/25

Optimistic Buy Rating for Perspective Therapeutics Amid Financial Stability and Promising Clinical Developments

Lila Implantra

TR | OpenAI - 4o

―

Hold

―

Upgraded

04/21/25

AI Generated ArticleAI Generated Article

Kemp Dolliver

Brookline Capital Markets

$11

Buy

205.56%

Upside

Initiated

03/10/25

Perspective Therapeutics initiated with a Buy at BrooklinePerspective Therapeutics initiated with a Buy at Brookline

Christopher Liu

Lucid Capital

$15→$20

Buy

455.56%

Upside

Reiterated

01/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Perspective Therapeutics

1 Month

xxx

Success Rate

10/14 ratings generated profit

Average Return

+11.69%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +11.69% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+38.66%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +38.66% per trade.

1 Year

Nicole GerminoTruist Financial

Success Rate

4/7 ratings generated profit

Average Return

+8.00%

reiterated a buy rating 2 months ago

Copying Nicole Germino's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +8.00% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+8.00%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +8.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CATX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CATX has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CATX average Analyst price target in the past 3 months is 14.11.

Each month's total comprises the sum of three months' worth of ratings.

CATX Financial Forecast

CATX Earnings Forecast

Next quarter’s earnings estimate for CATX is -$0.32 with a range of -$0.36 to -$0.26. The previous quarter’s EPS was -$0.30. CATX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year CATX has Outperformed its overall industry.

CATX Sales Forecast

Next quarter’s sales forecast for CATX is $204.00K with a range of $0.00 to $300.00K. The previous quarter’s sales results were $290.00K. CATX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year CATX has Outperformed its overall industry.

CATX Stock Forecast FAQ

What is CATX’s average 12-month price target, according to analysts?

Based on analyst ratings, Perspective Therapeutics, Inc.’s 12-month average price target is 14.11.

What is CATX’s upside potential, based on the analysts’ average price target?

Perspective Therapeutics, Inc. has 291.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CATX a Buy, Sell or Hold?

Perspective Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Perspective Therapeutics, Inc.’s price target?

The average price target for Perspective Therapeutics, Inc. is 14.11. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $6.00. The average price target represents 291.94% Increase from the current price of $3.6.

What do analysts say about Perspective Therapeutics, Inc.?

Perspective Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of CATX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Perspective Therapeutics (CATX) Stock Forecast & Price Target

CATX Analyst Ratings

CATX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Perspective Therapeutics

CATX Analyst Recommendation Trends

CATX Financial Forecast

CATX Earnings Forecast

CATX Sales Forecast

CATX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts